Consequently, combining PD-1 antibody and BTK inhibitor was demonstrated to possess a stronger synergistic antitumor reaction than any single one of them with a manageable safety profile, resulting in 40% objective response rate (ORR) among GCB-DLBCL patients (30). This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.